Wall Street questions Achillion HCV pipeline viability after sovaprevir setback
This article was originally published in Scrip
Executive Summary
As if the FDA's decision to maintain the clinical hold on Achillion's Phase I study of its investigational hepatitis C virus (HCV) medicine sovaprevir was not bad enough for the company – triggering a 60% sell off of its shares on 30 September – Wall Street analysts picked apart the company's interim results of an ongoing Phase IIa trial of the drug in combination with another of the firm's experimental HCV treatments, ACH-3102.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.